This review summarizes the current state of antiplatelet and anticoagulant therapy for cardiovascular disease, including their application in clinical devices and tissue engineering scaffolds.
This review highlights the dual role of anticoagulant and antiplatelet agents in systemic clinical therapy and as surface modifications for cardiovascular devices and tissue engineering.
An essential aspect of the treatment of patients with cardiovascular disease is the use of anticoagulant and antiplatelet agents for the prevention of further ischaemic events and vascular death resulting from thrombosis. Aspirin and heparin have been the standard therapy for the management of such conditions to date. Recently, numerous more potent platelet inhibitors together with anticoagulant agents have been developed and tested in randomized clinical trials. This article reviews the current state of the art of antiplatelet and anticoagulant therapy in light of its potential clinical efficacy. It then focuses on the usages of these agents in order to improve the performance of clinical devices such as balloon catheters, coronary stents, and femoropopliteal bypass grafting and extra corporeal circuits for cardiopulmonary bypass. The article then goes on to look at the usage of these agents more specifically heparin, heparan, hirudin, and coumarin in the development of more biocompatible scaffolds for tissue engineering.
Kidane et al. (Tue,) conducted a review in Cardiovascular disease. Anticoagulant and antiplatelet agents was evaluated. This review summarizes the current state of antiplatelet and anticoagulant therapy for cardiovascular disease, including their application in clinical devices and tissue engineering scaffolds.